Immuron (IMRN) Competitors

$0.79 -0.02 (-2.08%)

Closing price 05/5/2026 04:00 PM Eastern

Extended Trading

$0.79 0.00 (0.00%)

As of 05/5/2026 04:15 PM Eastern

IMRN vs. LSTA, NEUP, LTRN, ABVC, and AYTU

Should you be buying Immuron stock or one of its competitors? The main competitors of Immuron include Lisata Therapeutics (LSTA), Neuphoria Therapeutics (NEUP), Lantern Pharma (LTRN), ABVC BioPharma (ABVC), and Aytu BioPharma (AYTU). These companies are all part of the "med - biomed/gene" industry.

How does Immuron compare to Lisata Therapeutics?

Lisata Therapeutics (NASDAQ:LSTA) and Immuron (NASDAQ:IMRN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

: Lisata Therapeutics currently has a consensus price target of $15.00, suggesting a potential upside of 358.72%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than Immuron.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lisata Therapeutics
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Immuron
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: 8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 0.1% of Immuron shares are held by institutional investors. 9.1% of Lisata Therapeutics shares are held by company insiders. Comparatively, 7.0% of Immuron shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
: Immuron has higher revenue and earnings than Lisata Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lisata Therapeutics $170K 175.23 -$16.59M -$1.91 N/A
Immuron $7.48M 0.86 -$3.38M N/A N/A
: Lisata Therapeutics has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, Immuron has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.
: In the previous week, Lisata Therapeutics and Lisata Therapeutics both had 1 articles in the media. Lisata Therapeutics' average media sentiment score of 0.00 beat Immuron's score of -0.20 indicating that Lisata Therapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lisata Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Immuron
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Immuron's return on equity of 0.00% beat Lisata Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Lisata Therapeutics N/A -85.50% -70.85%
Immuron N/A N/A N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	175.23	-$16.59M	-$1.91	N/A
Immuron	$7.48M	0.86	-$3.38M	N/A	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lisata Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immuron	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-85.50%	-70.85%
Immuron	N/A	N/A	N/A

Summary

Lisata Therapeutics beats Immuron on 7 of the 12 factors compared between the two stocks.

How does Immuron compare to Neuphoria Therapeutics?

Immuron (NASDAQ:IMRN) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

: Neuphoria Therapeutics has a consensus price target of $21.00, suggesting a potential upside of 289.61%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neuphoria Therapeutics is more favorable than Immuron.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immuron
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Neuphoria Therapeutics
1 Sell rating(s)

1 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.25
: In the previous week, Immuron and Immuron both had 1 articles in the media. Neuphoria Therapeutics' average media sentiment score of 0.00 beat Immuron's score of -0.20 indicating that Neuphoria Therapeutics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immuron
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Neuphoria Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Immuron has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, Neuphoria Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500.
: 0.1% of Immuron shares are owned by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 7.0% of Immuron shares are owned by insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: Immuron's return on equity of 0.00% beat Neuphoria Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Immuron N/A N/A N/A
Neuphoria Therapeutics N/A -25.98% -18.39%
: Neuphoria Therapeutics has higher revenue and earnings than Immuron.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Immuron $7.48M 0.86 -$3.38M N/A N/A
Neuphoria Therapeutics $15.65M 1.86 -$370K -$4.42 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Neuphoria Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuron	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neuphoria Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Immuron	N/A	N/A	N/A
Neuphoria Therapeutics	N/A	-25.98%	-18.39%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuron	$7.48M	0.86	-$3.38M	N/A	N/A
Neuphoria Therapeutics	$15.65M	1.86	-$370K	-$4.42	N/A

Summary

Neuphoria Therapeutics beats Immuron on 8 of the 12 factors compared between the two stocks.

How does Immuron compare to Lantern Pharma?

Immuron (NASDAQ:IMRN) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immuron
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Lantern Pharma
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: In the previous week, Lantern Pharma had 4 more articles in the media than Immuron. MarketBeat recorded 5 mentions for Lantern Pharma and 1 mentions for Immuron. Lantern Pharma's average media sentiment score of -0.01 beat Immuron's score of -0.20 indicating that Lantern Pharma is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immuron
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Lantern Pharma
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
: Immuron has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, Lantern Pharma has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500.
: 0.1% of Immuron shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 7.0% of Immuron shares are owned by insiders. Comparatively, 8.5% of Lantern Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: Immuron's return on equity of 0.00% beat Lantern Pharma's return on equity.
Company Net Margins Return on Equity Return on Assets
Immuron N/A N/A N/A
Lantern Pharma N/A -150.76% -108.38%
: Immuron has higher revenue and earnings than Lantern Pharma.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Immuron $7.48M 0.86 -$3.38M N/A N/A
Lantern Pharma N/A N/A -$17.12M -$1.57 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuron	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lantern Pharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Immuron	N/A	N/A	N/A
Lantern Pharma	N/A	-150.76%	-108.38%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuron	$7.48M	0.86	-$3.38M	N/A	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.57	N/A

Summary

Lantern Pharma beats Immuron on 5 of the 9 factors compared between the two stocks.

How does Immuron compare to ABVC BioPharma?

Immuron (NASDAQ:IMRN) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immuron
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
ABVC BioPharma
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Immuron has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, ABVC BioPharma has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500.
: In the previous week, Immuron had 1 more articles in the media than ABVC BioPharma. MarketBeat recorded 1 mentions for Immuron and 0 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 0.00 beat Immuron's score of -0.20 indicating that ABVC BioPharma is being referred to more favorably in the news media.
Company Overall Sentiment
Immuron Neutral
ABVC BioPharma Neutral
: Immuron's return on equity of 0.00% beat ABVC BioPharma's return on equity.
Company Net Margins Return on Equity Return on Assets
Immuron N/A N/A N/A
ABVC BioPharma N/A -65.11% -40.13%
: 0.1% of Immuron shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 7.0% of Immuron shares are held by insiders. Comparatively, 19.0% of ABVC BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: Immuron has higher revenue and earnings than ABVC BioPharma.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Immuron $7.48M 0.86 -$3.38M N/A N/A
ABVC BioPharma $510K 51.38 -$7.91M -$0.40 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Overall Sentiment
Immuron	Neutral
ABVC BioPharma	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Immuron	N/A	N/A	N/A
ABVC BioPharma	N/A	-65.11%	-40.13%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuron	$7.48M	0.86	-$3.38M	N/A	N/A
ABVC BioPharma	$510K	51.38	-$7.91M	-$0.40	N/A

Summary

Immuron beats ABVC BioPharma on 6 of the 10 factors compared between the two stocks.

How does Immuron compare to Aytu BioPharma?

Immuron (NASDAQ:IMRN) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

: Aytu BioPharma has a consensus price target of $9.33, suggesting a potential upside of 263.16%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Aytu BioPharma is more favorable than Immuron.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immuron
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Aytu BioPharma
2 Sell rating(s)

0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.20
: Immuron has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500.
: In the previous week, Aytu BioPharma had 1 more articles in the media than Immuron. MarketBeat recorded 2 mentions for Aytu BioPharma and 1 mentions for Immuron. Aytu BioPharma's average media sentiment score of 0.00 beat Immuron's score of -0.20 indicating that Aytu BioPharma is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immuron
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aytu BioPharma
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Immuron has a net margin of 0.00% compared to Aytu BioPharma's net margin of -39.02%. Immuron's return on equity of 0.00% beat Aytu BioPharma's return on equity.
Company Net Margins Return on Equity Return on Assets
Immuron N/A N/A N/A
Aytu BioPharma -39.02% -28.22% -5.20%
: 0.1% of Immuron shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 7.0% of Immuron shares are held by insiders. Comparatively, 4.9% of Aytu BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: Immuron has higher earnings, but lower revenue than Aytu BioPharma.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Immuron $7.48M 0.86 -$3.38M N/A N/A
Aytu BioPharma $66.38M 0.42 -$13.56M -$3.84 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aytu BioPharma	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuron	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aytu BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Immuron	N/A	N/A	N/A
Aytu BioPharma	-39.02%	-28.22%	-5.20%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuron	$7.48M	0.86	-$3.38M	N/A	N/A
Aytu BioPharma	$66.38M	0.42	-$13.56M	-$3.84	N/A

Summary

Immuron and Aytu BioPharma tied by winning 7 of the 14 factors compared between the two stocks.

Get Immuron News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMRN vs. The Competition

Export

Metric	Immuron	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.58M	$3.40B	$6.25B	$11.76B
Dividend Yield	N/A	2.23%	2.74%	5.26%
P/E Ratio	N/A	38.57	29.24	27.07
Price / Sales	0.86	280.01	504.68	73.40
Price / Cash	N/A	125.06	43.30	53.90
Price / Book	1.01	7.05	9.67	6.69
Net Income	-$3.38M	$23.62M	$3.55B	$332.64M
7 Day Performance	-2.35%	5.87%	3.02%	3.07%
1 Month Performance	-0.75%	6.33%	5.13%	7.80%
1 Year Performance	-59.33%	78.43%	38.78%	41.57%

Immuron Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMRN Immuron	0.2267 of 5 stars	$0.79 -2.1%	N/A	-58.8%	$6.58M	$7.48M	N/A	N/A	Earnings Report
LSTA Lisata Therapeutics	1.3642 of 5 stars	$3.20 +2.6%	$15.00 +368.8%	+35.9%	$28.18M	$170K	N/A	30	Upcoming Earnings
NEUP Neuphoria Therapeutics	2.212 of 5 stars	$5.12 -0.6%	$21.00 +310.2%	+4.1%	$27.76M	$15.65M	N/A	N/A	News Coverage Positive News Gap Down
LTRN Lantern Pharma	0.3398 of 5 stars	$2.24 -8.9%	N/A	-41.1%	$27.69M	N/A	N/A	20
ABVC ABVC BioPharma	0.2377 of 5 stars	$1.07 -0.9%	N/A	-8.0%	$27.48M	$510K	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMRN) was last updated on 5/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immuron (IMRN) Competitors

IMRN vs. LSTA, NEUP, LTRN, ABVC, and AYTU

How does Immuron compare to Lisata Therapeutics?

Summary

How does Immuron compare to Neuphoria Therapeutics?

Summary

How does Immuron compare to Lantern Pharma?

Summary

How does Immuron compare to ABVC BioPharma?

Summary

How does Immuron compare to Aytu BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRN vs. The Competition

Immuron Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immuron (IMRN) Competitors

IMRN vs. LSTA, NEUP, LTRN, ABVC, and AYTU

How does Immuron compare to Lisata Therapeutics?

Summary

How does Immuron compare to Neuphoria Therapeutics?

Summary

How does Immuron compare to Lantern Pharma?

Summary

How does Immuron compare to ABVC BioPharma?

Summary

How does Immuron compare to Aytu BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRN vs. The Competition

Immuron Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools